Japanese pharmaceuticals company says ivermectin shows ‘antiviral effect’ against Omicron

Firm has been working with Kitasato University, a medical university in Tokyo, on testing the drug as a potential Covid-19 treatment

Sravasti Dasgupta
Tuesday 01 February 2022 11:45 GMT
Comments
Ivermectin Explained: Why the Anti-Parasite Drug Has Emerged in COVID Debate

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

Japan’s trading and pharmaceutical company Kowa Co Ltd said on Monday that anti-parasitic drug ivermectin has an “anti-viral” effect against the Omicron variant of the coronavirus.

The firm has been working with Kitasato University, a medical university in Tokyo, on testing the drug as a potential Covid-19 treatment.

In a press release the company said that phase three non-clinical trial of the drug has shown anti-viral effect against Omicron as well as other coronavirus variants, reported Reuters.

The company did not, however, share any further details.

Ivermectin has been controversially touted as a potential treatment for Covid since the earliest stages of the pandemic.

The US Food and Drug Administration has warned against using it as a treatment or as a preventive measure against Covid-19.

A European Medicines Agency review in March found that “the available data do not support its use for Covid-19 outside well-designed clinical trials”.

The WHO has also warned against using “ivermectin in patients with Covid-19”.

A clinical trial is underway in the UK by the university of Oxford to test the drug’s potential in treating Covid.

Researchers told Reuters on Monday that the trial is still underway, and no comment can be issued unless the results are found.

The drug’s use has generated controversy with prominent US anti-vaxxer Joe Rogan also claiming to have used it.

His podcast on Spotify has generated protests against misinformation on the platform from artists including Neil Young and Joni Mitchell.

In 2020, a peer-reviewed Australian study found that ivermectin could kill Covid in a lab, prompting some commentators to promote the drug among humans despite warnings from globally trusted public health institutions that have advised against its use for treating Covid.

Other potential Covid treatments that showed promise in labs include the antimalarial drug hydroxychloroquine promoted by former US president Donald Trump.

The drug ultimately failed to show benefit for Covid patients in clinical trials.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in